BWAY

BWAY

USD

BrainsWay Ltd. American Depositary Shares

$9.210+0.020 (0.218%)

Reaalajas hind

Healthcare
Meditsiiniseadmed
Iisrael

Hinnagraafik

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$9.190

Kõrge

$9.239

Madal

$8.952

Maht

0.00M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

173.8M

Tööstusharu

Meditsiiniseadmed

Riik

Israel

Kauplemisstatistika

Keskmine maht

0.06M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $4.8Praegune $9.210Kõrge $11.79

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 22. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

BWAY (BrainsWay Ltd. American Depositary Shares): Analyzing Recent Moves & What Might Come Next

Stock Symbol: BWAY Generate Date: 2025-04-22 16:58:14

Okay, let's break down what's been going on with BrainsWay (BWAY) based on the latest info we have. We'll look at the news, check out the price chart, and see what the AI model is predicting for the very near future.

What's Been Happening? (News & Price Check)

Recent News Buzz:

We've got a couple of news items here. One from back in late February announced the date for the company's fourth-quarter and full-year 2024 financial results – that was set for March 11th. This kind of news is pretty standard; it just tells you when to expect the numbers. The results themselves, which came out after that date, would be the real driver, but the news provided is just the announcement of the date.

The other piece of news, from March 12th, is more directly about the stock's potential. An analyst over at HC Wainwright & Co., Raghuram Selvaraju, reiterated their "Buy" rating on BrainsWay and kept their price target at a solid $16. Now, that's a pretty bullish signal from an analyst, suggesting they think the stock has a lot of room to grow from where it is now.

Looking at the Price:

When you check out the stock's price action over the last few months, it tells a different story than that analyst target, at least recently. Back in January and early February, the stock was trading mostly between $10 and $11. It even saw a nice bump in mid-February, hitting a 52-week high near $11.80.

But then things shifted. Around the time of that earnings announcement date in March, the price took a noticeable dip. It spent most of March bouncing around between $9 and $10. Fast forward to April, and the trend has continued downwards. The stock has dropped into the $8 range. The last price point we have shows it trading around $8.09 to $8.51 on April 22nd. So, the clear recent trend, especially over the last month or so, has been a move lower.

Looking Ahead (AI Prediction & What it Might Mean)

The AI's Short-Term View:

The AI prediction model gives us a peek at the next couple of days. It's predicting very small positive movements: 0.0% for today (which is essentially flat), then a modest 1.85% increase the next day, followed by another 2.07% bump the day after that.

What does this suggest? The AI isn't forecasting a massive surge, but it seems to think the stock might see a small bounce or stabilization in the immediate future from its current lower level.

Putting it Together:

So, where does this leave us? We have an analyst who thinks the stock is worth $16 (a long-term view), but the actual market price has been trending down significantly lately, now sitting around $8.00-$8.50. The AI model, looking only a couple of days out, predicts a slight upward nudge from this lower point.

This creates a bit of a mixed picture. The strong recent downtrend is the dominant price signal. However, the analyst's high price target and the AI's prediction of a small near-term bounce from the current level offer potential counterpoints.

Given the recent price drop, the AI's prediction of a small bounce could suggest that the stock is potentially oversold in the very short term and might see a minor recovery. The analyst target remains a long-term bullish view, but the market hasn't been following it lately.

Thinking About Strategy (Potential Ideas Based on Data)

Based strictly on the AI's prediction of a small bounce from the current low area, and considering the recent price decline, the situation might lean towards a potential short-term 'buy' or 'accumulate' idea if you're betting on that specific AI forecast playing out.

  • Potential Entry Consideration: If someone were looking to play that potential short-term bounce predicted by the AI, an entry could be considered around the current price area, perhaps between $8.00 and $8.15. This range is right where the stock has been trading after its recent drop and aligns with the levels where the AI sees potential for a small move up. The recommendation data also points to potential entry points around $7.98 and $8.13, which fits this picture.
  • Potential Exit/Risk Management: Managing risk is always key. If you were to enter based on a potential bounce, where might you look to take profits or cut losses? The recommendation data suggests a potential take profit level around $9.05. This is near the higher end of the range the stock traded in during late March before its further decline. For managing downside risk, a stop-loss level around $7.19 is suggested in the data. This is below the recent lows and provides a point to exit if the price continues to fall instead of bouncing.

Remember, these are just potential ideas derived from the provided data points and AI prediction. The recent price trend has been negative, which is a significant factor to consider.

Quick Company Note

Just a quick reminder about BrainsWay itself: it's a medical device company focused on using noninvasive technology (Deep Transcranial Magnetic Stimulation) to treat mental health conditions like depression and OCD. This means news about clinical trials, regulatory approvals (like FDA clearance), insurance coverage, or adoption by doctors and hospitals are really important drivers for their business and stock price. The recent price drop could be related to factors not covered in the limited news provided, perhaps related to those Q4/FY24 results that were announced after the news date.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions. Past performance and AI predictions are not guarantees of future results.

Seotud uudised

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay with a Buy and maintains $16 price target.

Vaata rohkem
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target
GlobeNewswire

BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

BURLINGTON, Mass. and JERUSALEM, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments

Vaata rohkem
BrainsWay to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 28. apr 2025, 05:51

LangevNeutraalneTõusev

61.4% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Kasv
Kauplemisjuhend

Sisenemispunkt

$9.08

Võta kasum

$9.32

Peata kahjum

$8.23

Põhitegurid

PDI 28.9 on MDI 25.9 kohal ADX-iga 14.3, mis viitab tõusutrendile
Praegune hind läheneb tugitasemele ($9.06), tasub jälgida
MACD 0.0472 on signaalijoone 0.0625 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.